Cargando…

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

Behçet disease (BD) is a multisystem disease associated with a poor prognosis in cases of gastrointestinal, neurological, or vascular involvement. We conducted a multicenter, prospective, open-label, single-arm phase 3 study to determine the efficacy, safety, and pharmacokinetics of infliximab (IFX)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibi, Toshifumi, Hirohata, Shunsei, Kikuchi, Hirotoshi, Tateishi, Ukihide, Sato, Noriko, Ozaki, Kunihiko, Kondo, Kazuoki, Ishigatsubo, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998455/
https://www.ncbi.nlm.nih.gov/pubmed/27310969
http://dx.doi.org/10.1097/MD.0000000000003863
_version_ 1782449946484539392
author Hibi, Toshifumi
Hirohata, Shunsei
Kikuchi, Hirotoshi
Tateishi, Ukihide
Sato, Noriko
Ozaki, Kunihiko
Kondo, Kazuoki
Ishigatsubo, Yoshiaki
author_facet Hibi, Toshifumi
Hirohata, Shunsei
Kikuchi, Hirotoshi
Tateishi, Ukihide
Sato, Noriko
Ozaki, Kunihiko
Kondo, Kazuoki
Ishigatsubo, Yoshiaki
author_sort Hibi, Toshifumi
collection PubMed
description Behçet disease (BD) is a multisystem disease associated with a poor prognosis in cases of gastrointestinal, neurological, or vascular involvement. We conducted a multicenter, prospective, open-label, single-arm phase 3 study to determine the efficacy, safety, and pharmacokinetics of infliximab (IFX) in BD patients with these serious complications who had displayed poor response or intolerance to conventional therapy. IFX at 5 mg/kg was administered to 18 patients (11 intestinal BD, 3 neurological BD [NBD], and 4 vascular BD [VBD]) at weeks 0, 2, and 6 and every 8 weeks thereafter until week 46. In patients who showed inadequate responses to IFX after week 30, the dose was increased to 10 mg/kg. We then calculated the percentage of complete responders according to the predefined criteria depending on the symptoms and results of examinations (ileocolonoscopy, brain magnetic resonance imaging, computed tomography angiography, positron emission tomography, cerebrospinal fluid, or serum inflammatory markers), exploring the percentage of complete responders at week 30 (primary endpoint). The percentage of complete responders was 61% (11/18) at both weeks 14 and 30 and remained the same until week 54. Intestinal BD patients showed improvement in clinical symptoms along with decrease in C-reactive protein (CRP) levels after week 2. Consistently, scarring or healing of the principal ulcers was found in more than 80% of these patients after week 14. NBD patients showed improvement in clinical symptoms, imaging findings, and cerebrospinal fluid examinations. VBD patients showed improvement in clinical symptoms after week 2 with reductions in CRP levels and erythrocyte sedimentation rate. Imaging findings showed reversal of inflammatory changes in 3 of the 4 VBD patients. Irrespective of the type of BD, all patients achieved improvement in quality of life, leading to the dose reduction or withdrawal of steroids. IFX dose was increased to 10 mg/kg in 3 intestinal BD patients, resulting in the improvement of clinical symptoms, CRP levels, and visual analogue scale score. Safety and pharmacokinetics profiles were comparable to those in patients with rheumatoid arthritis or Crohn disease. These findings support IFX as a new therapeutic option for patients with intestinal BD, NBD, or VBD.
format Online
Article
Text
id pubmed-4998455
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49984552016-09-02 Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study Hibi, Toshifumi Hirohata, Shunsei Kikuchi, Hirotoshi Tateishi, Ukihide Sato, Noriko Ozaki, Kunihiko Kondo, Kazuoki Ishigatsubo, Yoshiaki Medicine (Baltimore) 6900 Behçet disease (BD) is a multisystem disease associated with a poor prognosis in cases of gastrointestinal, neurological, or vascular involvement. We conducted a multicenter, prospective, open-label, single-arm phase 3 study to determine the efficacy, safety, and pharmacokinetics of infliximab (IFX) in BD patients with these serious complications who had displayed poor response or intolerance to conventional therapy. IFX at 5 mg/kg was administered to 18 patients (11 intestinal BD, 3 neurological BD [NBD], and 4 vascular BD [VBD]) at weeks 0, 2, and 6 and every 8 weeks thereafter until week 46. In patients who showed inadequate responses to IFX after week 30, the dose was increased to 10 mg/kg. We then calculated the percentage of complete responders according to the predefined criteria depending on the symptoms and results of examinations (ileocolonoscopy, brain magnetic resonance imaging, computed tomography angiography, positron emission tomography, cerebrospinal fluid, or serum inflammatory markers), exploring the percentage of complete responders at week 30 (primary endpoint). The percentage of complete responders was 61% (11/18) at both weeks 14 and 30 and remained the same until week 54. Intestinal BD patients showed improvement in clinical symptoms along with decrease in C-reactive protein (CRP) levels after week 2. Consistently, scarring or healing of the principal ulcers was found in more than 80% of these patients after week 14. NBD patients showed improvement in clinical symptoms, imaging findings, and cerebrospinal fluid examinations. VBD patients showed improvement in clinical symptoms after week 2 with reductions in CRP levels and erythrocyte sedimentation rate. Imaging findings showed reversal of inflammatory changes in 3 of the 4 VBD patients. Irrespective of the type of BD, all patients achieved improvement in quality of life, leading to the dose reduction or withdrawal of steroids. IFX dose was increased to 10 mg/kg in 3 intestinal BD patients, resulting in the improvement of clinical symptoms, CRP levels, and visual analogue scale score. Safety and pharmacokinetics profiles were comparable to those in patients with rheumatoid arthritis or Crohn disease. These findings support IFX as a new therapeutic option for patients with intestinal BD, NBD, or VBD. Wolters Kluwer Health 2016-06-17 /pmc/articles/PMC4998455/ /pubmed/27310969 http://dx.doi.org/10.1097/MD.0000000000003863 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 6900
Hibi, Toshifumi
Hirohata, Shunsei
Kikuchi, Hirotoshi
Tateishi, Ukihide
Sato, Noriko
Ozaki, Kunihiko
Kondo, Kazuoki
Ishigatsubo, Yoshiaki
Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
title Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
title_full Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
title_fullStr Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
title_full_unstemmed Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
title_short Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
title_sort infliximab therapy for intestinal, neurological, and vascular involvement in behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
topic 6900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998455/
https://www.ncbi.nlm.nih.gov/pubmed/27310969
http://dx.doi.org/10.1097/MD.0000000000003863
work_keys_str_mv AT hibitoshifumi infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT hirohatashunsei infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT kikuchihirotoshi infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT tateishiukihide infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT satonoriko infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT ozakikunihiko infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT kondokazuoki infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study
AT ishigatsuboyoshiaki infliximabtherapyforintestinalneurologicalandvascularinvolvementinbehcetdiseaseefficacysafetyandpharmacokineticsinamulticenterprospectiveopenlabelsinglearmphase3study